[HTML][HTML] TGF-β and fibrosis in different organs—molecular pathway imprints

D Pohlers, J Brenmoehl, I Löffler, CK Müller… - … et Biophysica Acta (BBA …, 2009 - Elsevier
D Pohlers, J Brenmoehl, I Löffler, CK Müller, C Leipner, S Schultze-Mosgau, A Stallmach
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2009Elsevier
The action of transforming-growth-factor (TGF)-β following inflammatory responses is
characterized by increased production of extracellular matrix (ECM) components, as well as
mesenchymal cell proliferation, migration, and accumulation. Thus, TGF-β is important for
the induction of fibrosis often associated with chronic phases of inflammatory diseases. This
common feature of TGF-related pathologies is observed in many different organs. Therefore,
in addition to the description of the common TGF-β-pathway, this review focuses on TGF-β …
The action of transforming-growth-factor (TGF)-β following inflammatory responses is characterized by increased production of extracellular matrix (ECM) components, as well as mesenchymal cell proliferation, migration, and accumulation. Thus, TGF-β is important for the induction of fibrosis often associated with chronic phases of inflammatory diseases. This common feature of TGF-related pathologies is observed in many different organs. Therefore, in addition to the description of the common TGF-β-pathway, this review focuses on TGF-β-related pathogenetic effects in different pathologies/organs, i. e., arthritis, diabetic nephropathy, colitis/Crohn's disease, radiation-induced fibrosis, and myocarditis (including their similarities and dissimilarities). However, TGF-β exhibits both exacerbating and ameliorating features, depending on the phase of disease and the site of action. Due to its central role in severe fibrotic diseases, TGF-β nevertheless remains an attractive therapeutic target, if targeted locally and during the fibrotic phase of disease.
Elsevier